Literature DB >> 10746977

HLA class I antigens expression in renal cell carcinoma: histopathological and clinical correlation.

D Brasanac1, C A Müller, G A Müller, J Hadzi-Dzokic, J Markovic-Lipkovski.   

Abstract

Immunohistochemical analysis of HLA class I antigens expression in 26 renal cell carcinomas (RCCs)--18 clear cell, 6 granular and 2 chromophobe--was performed with indirect immunoperoxidase method. Results were correlated with extent and immunophenotype of tumor infiltrating mononuclear cells, histopathological (histology, cytology, grade, presence of necrosis) and clinical (tumor diameter, TNM classification) characteristics of RCC. 4 (15%) RCCs showed reduced HLA class I presence and this was associated with greater tumor diameter and more frequent T3, T4 and M1 stage. All tumors with altered HLA class I antigens expression were grade 2 or 3 and strong correlation with presence of necrosis (p=0.006) was noticed, while mononuclear cell infiltrates (especially CD8+ T lymphocytes) were less extensive compared to tumors with normal HLA class I level. Our results suggest more aggressive clinical behavior of RCCs with reduced HLA class I antigens expression, probably due to impaired cellular antitumor immune response.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10746977

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  2 in total

1.  The relationship between human leukocyte antigens (HLA) and renal cell carcinoma.

Authors:  Erkan Yilmaz; Arman Çekmen; Emre Akkuş; Bülent Önal; Ali Uğur Özalp; Vural Solok; Ergun Erdoğan; Bülent Eren
Journal:  Bosn J Basic Med Sci       Date:  2010-11       Impact factor: 3.363

2.  Major histocompatibility complex I upregulation in clear cell renal cell carcinoma is associated with increased survival.

Authors:  Rishi R Sekar; Claire M De La Calle; Dattatraya Patil; Sarah A Holzman; Yoram Baum; Umer Sheikh; Jonathan H Huang; Adeboye O Osunkoya; Brian P Pollack; Haydn T Kissick; Kenneth Ogan; Viraj A Master
Journal:  Asian J Urol       Date:  2016-02-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.